SIC 2834 – Pharmaceutical Preparations
Valuation | |
---|---|
Market Cap ($M) | 26.15 |
Enterprise Value ($M) | 15.37 |
Book Value ($M) | 10.92 |
Book Value / Share | 2.99 |
Price / Book | 2.39 |
NCAV ($M) | 10.86 |
NCAV / Share | 2.97 |
Price / NCAV | 2.41 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | -0.88 |
Return on Assets (ROA) | -0.28 |
Return on Equity (ROE) | -0.54 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 19.40 |
Current Ratio | 19.40 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 11.45 |
Assets | 11.51 |
Liabilities | 0.59 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 0.00 |
Operating Income | 0.00 |
Net Income | 0.00 |
Earnings Per Share Basic And Diluted | n/a |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | 0.00 |
Cash from Investing | 0.00 |
Cash from Financing | 0.00 |
(click for more detail) |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
File Date | Form | SEC Filings |
---|---|---|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
8,657 | 57,326 | 15.10 | |
2,395 | 16,331 | 14.67 | |
3,377 | 24,833 | 13.60 | |
2,433 | 12,671 | 19.20 | |
(click for more detail) |
Similar Companies | |
---|---|
PRTG – Portage Biotech Inc. | PTIX – Protagenic Therapeutics, Inc. |
PTPI – Petros Pharmaceuticals, Inc. | QLGN – Qualigen Therapeutics, Inc. |
RENB – Renovaro Inc. |